

RSS: OB/GYN Grand Rounds 2024

Session Date: March 15, 2024 ● 8:00 AM – 9:00 AM

Title: OB/GYN Grand Rounds 2024 - Xylazine: A Growing Threat in Perinatal SUD Care; Presented by Ilana Hull, MD

Session Speaker:

Ilana Hull, MD
Physician
University of Pittsburgh

Accreditation:

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Medical Association (AMA)

Dartmouth Health designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Learning Objectives:

At the conclusion of this learning activity, participants will be able to:

- 1 • Discuss the emergence of xylazine as a common adulterant in the illicit opioid supply in the United States and review recent national trends.
- 2 • Discuss potential clinical harms and public health implications of combined xylazine and opioid exposures.
- 3 • Review best practices for clinical management of xylazine exposure in pregnancy and harm reduction strategies.

Dartmouth Health adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies[^]. All relevant financial relationships have been mitigated prior to the commencement of the activity.

[^]*Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.*

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Tina C Foster, MD	Other Planning Committee Member	Nothing to disclose - 01/24/2024
Rebecca H Evans, MD	Other Planning Committee Member	Nothing to disclose - 10/19/2023
Ilana Cass, MD	Other Planning Committee Member	Nothing to disclose - 11/01/2023
Robert N Blatman, MD	Course Director	Nothing to disclose - 01/04/2024
Katelyn M. Danner	Activity Coordinator	Nothing to disclose - 10/09/2023
Ilana Hull, MD	Faculty	Nothing to disclose - 02/22/2024

Mobile Text-In Code for this Session Only

<Code>

Code Expires in 48 Hours

Text Requests for Credit to this Number:
(833-884-3375)

Need help?
clpd.support@hitchcock.org

Create New Account
dh.cloud-cme.com